The brain drug that lost weight by accident. Tesofensine is one of the register's best serendipity stories — and a mechanistic outlier. Beautiful facts: (1) it was built for Parkinson's and Alzheimer's, worked only modestly there, but made patients lose weight so consistently the whole program pivot
Tesofensine (NS-2330) is a small-molecule triple monoamine reuptake inhibitor — it raises dopamine, norepinephrine, and serotonin at once — and its story is a gem of pharmacological serendipity. It was developed for Parkinson's and Alzheimer's, where it worked only modestly, but trial participants lost weight so reliably that the program pivoted entirely to obesity — a weight-loss effect discovered, not designed. A pooled analysis of neurology trials revealed the dose-dependent effect, and a Phase 2 obesity trial (Lancet 2008) showed ~10% weight loss in 24 weeks — about double the approved drugs of that era. Mechanistically it's an outlier here: it works centrally, on two fronts at once (appetite suppression via serotonin, energy expenditure via norepinephrine), rather than through gut incretin or amylin hormones. The honest caveats are real: it's a small molecule (not a peptide), unapproved, its mechanism is cousin to withdrawn appetite drugs (sibutramine), and it carries a cardiovascular signal (raised heart rate). And its headline "twice the weight loss" belongs to a pre-GLP-1 world — today's semaglutide/tirzepatide have reset the bar. So: a fascinating, twice-serendipitous CNS weight-loss drug with a genuinely interesting mechanism — but unapproved, cardiovascularly watchful, and overtaken by the incretin era.
not an approved obesity drug in major markets; investigational (reached Phase 2/3). Some regional/combination development has occurred, but no broad approval.
An honest grade per outcome — drawn from the evidence, not any catalogue. Hype and undemonstrated marketing claims grade low.
A credentialed reviewer (PharmD / PhD / MD) will be named before this entry is finalised. Until then, treat it as a working draft. Last updated July 2026 (status: Phase 2/3 investigational; the open questions are Phase 3 confirmation and cardiovascular safety — and whether any CNS-monoamine drug can compete with the incretin era).
Grades reflect the published evidence, not our interest. No dosing, reconstitution, or administration is published for research compounds — that restraint is deliberate.
A neutral reference and a lawful-lane shop. Registered in Spain. Information for those who seek it — never promotion.
This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia SL — Registered in Spain.